MaxWell Biosystems Company

MaxWell Biosystems AG provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery. MaxWell Biosystems develops and markets advanced electrophysiology platforms for cell assays in preclinical drug discovery, safety pharmacology and basic neuroscience research. MaxOne (single-well) and MaxTwo (multi-well) allow stimulation and recording of every active cell on a dish at unprecedented spatio-temporal resolution. These instruments will advance and accelerate drug discovery and basic neurosciences.

Cell types: Neurons, cardiomyocytes, induced pluripotent stem cell (iPSC), others. Preparations: acute brain slice and retina, dissociated cell culture, organotypic slice culture, embryoid body. Applications: phenotype screening, detailed single cell analysis, multi-parametric network analysis, drug efficacy testing, toxicity testing
Technology: P4 Medicine
Industry: P4 Medicine
Headquarters: Basel, Basel-Stadt, Switzerland
Founded Date: 7-8
Employees Number: 11-50
Funding Status: Undisclosed
Investors Number: 2
Total Funding: $211.5K
Estimated Revenue: $1M to $10M
Last Funding Type: Grant

Visit Website
Register and Claim Ownership